Researchers have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell. When the researchers increased the mitochondrial content with an inhibitor, the cancer cells responded to the treatment. Their findings, which are published in Nature Metabolism, offer hope for more targeted cancer drugs.
Mitochondria produce energy for the cell and require oxygen to do so. As such, they are the most oxygen-demanding component of the cell. But how mitochondria adapt in a low-oxygen environment and are linked to cancer therapy resistance has remained unknown.
“We’ve shown for the first time how the formation of new mitochondria is regulated in cells that lack oxygen and how this process is altered in cancer cells with VHL mutations,” says the group leader.
Healthy cells are prevented from becoming cancerous by a gene called von Hippel-Lindau (VHL). The 2019 Nobel Prize in Physiology or Medicine was awarded to the discovery that VHL was part of the cell’s oxygen detection system. Normally, VHL breaks down another protein called HIF. Consequently, when VHL is mutated, HIF accumulates and causes a disease called VHL syndrome in which the cells react as if they lack oxygen despite oxygen being present. VHL syndrome greatly increases the risk of tumors, both benign and malignant. VHL syndrome-induced kidney cancer has a poor prognosis, with a five-year survival rate of barely 12 per cent.
In the present study, the researchers examined the protein content of cancer cells from patients with different variants of VHL syndrome, and how they differed from another group of individuals with a special VHL mutation called Chuvash, a mutation involved in hypoxia-sensing disorders without any tumor development. Those with the Chuvash VHL-mutation had normal mitochondria in their cells, while those with VHL syndrome mutation had few.
To increase the amount of mitochondrial content in VHL related kidney cancer cells, the researchers treated these tumors with an inhibitor of a mitochondrial protease called “LONP1”. The cells then became susceptible to the cancer drug sorafenib, which they had previously resisted. In mouse studies, this combination treatment led to reduced tumor growth.
“We hope that this new knowledge will pave the way for more specific LONP1 protease inhibitors to treat VHL-related clear cell kidney cancer,” says the study’s first author. “Our finding can be linked to all VHL syndromic cancers, such as the neuroendocrine tumors pheochromocytoma and paraganglioma, and not just kidney cancer.”
https://www.nature.com/articles/s42255-022-00593-x
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fimpaired-oxygen&filter=22
Role of mitochondrial biogenesis in deadly kidney cancer
- 371 views
- Added
Latest News
Mosquitoes have neuronal fail-safes to make sure they can always smell humans
Detecting gut microbes that activate immune cells
Shell microelectrode arrays (MEAs) for brain organoids
Why heat makes us sleepy
Nasal spray peptide can reduce seizure activity, protect neurons in Alzheimer's
Other Top Stories
mRNA methylation differentiates diseased beta cells in type 2 diabetes
Linking nicotine addiction to increased risk for diabetes via brain-pancreas signaling axis
Secretomes of human brown and white fat
Gene function that protects against type 2 diabetes discovered!
Organoids from islet and amniotic epithelial cells to treat diabetes
Protocols
Simultaneous recording of neuronal and vascular activity in the rodent brain using fiber- photom…
VDJdb in the pandemic era: a compendium of T cell receptors specifc for SARS-CoV-2
A scalable organoid model of human autosomal dominant polycystic kidney disease for disease mecha…
An improved organotypic cell culture system to study tissue-resident macrophages ex vivo
Protocol for spike-triggered closed-loop auditory stimulation during sleep in patients with epilepsy
Publications
Bipolar-associated miR-499-5p controls neuroplasticity by downregulating the Cav1.2 subunit CACNB2
Non-canonical odor coding in the mosquito
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weig…
Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communicat…
Systemic inflammation after stroke: implications for post-stroke comorbidities
Presentations
Hydrogels in Drug Delivery
Lipids
Cell biology of carbohydrate metabolism
RNA interference (RNAi)
RNA structure and functions
Posters
ASCO-2020-HEALTH SERVICES RESEARCH AND QUALITY IMPROVEMENT
ASCO-2020-HEAD AND NECK CANCER
ASCO-2020-GENITOURINARY CANCER–KIDNEY AND BLADDER
ASCO-2020-GENITOURINARY CANCER–PROSTATE, TESTICULAR, AND PENILE
ASCO-2020-GYNECOLOGIC CANCER